Mayo Clinic
This study is being done to find out if patient blood samples can be used to perform individualized modeling of cancer therapy-related side effects.
PRIMARY OBJECTIVES: I. Generate induced pluripotent stem cells (iPSC's) from patients receiving cancer treatment. II. Differentiate patient iPSC's into cardiomyocytes and/or neurons or other cell types that may be relevant to modeling cancer therapy-related adverse effects, such as cardiotoxicity and neurotoxicity. III. Use patient specific iPSC-derived cells to: IIIa. Model cancer therapy-related toxicities; IIIb. Better understand the mechanisms of toxicities; IIIc. Determine if patient specific genetic variants are causative of toxicities; IIId. Screen novel protective therapies for can…
Inclusion Criteria: * Any patient \>= 18 years of age * Previously treated, planned or currently receiving any potentially toxic cancer therapy including but not limited to chemotherapy, targeted and immunotherapies Exclusion Criteria: * Inability on the part of the patient to understand the informed consent or be compliant with the protocol
Non-interventional study
Arctuva estimate
Verify or correct the compensation shown for this listing.